Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide

JNemchinova/iStock via Getty Images

  • Zealand Pharma (OTCPK:ZLDPF) said that top-line phase 2 results of its GLP-1/GLP-2 receptor dual agonist dapiglutide show promise as a weight loss treatment.
  • Data indicated that after 12 weeks, those on dapiglutide at 4 mg and 6 mg doses had a mean weight

Source link
Exit mobile version